Biogen's (NASDAQ: BIIB) stock caught fire yesterday. Although the biotech posted stellar third-quarter results that surpassed analysts' expectations ahead of the opening bell on Tuesday, the real market-mover proved to be the unexpected news about its Alzheimer's disease candidate, aducanumab.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,